Johnson & Johnson partners with Sail Biomedicines on in vivo CAR‑T with $2.58B acquisition option
- Johnson & Johnson will make $785 million in initial payments, including a $465 million equity investment by its corporate VC arm, plus $140 million in contingent development milestones.
- The deal grants Johnson & Johnson an exclusive option to acquire Sail for $2.58 billion, payable if the option is exercised.
- Collaboration targets Sail’s lead in vivo CAR‑T program to reprogram immune cells in the body for durable immune reset in immune‑mediated diseases.
- Assuming exercise of the option, Johnson & Johnson expects dilution to adjusted operational EPS of about $0.18 in 2026 and $1.28 in 2027; transactions are subject to regulatory approvals.
Deal structure
Johnson & Johnson entered strategic agreements and an equity investment to collaborate with Sail Biomedicines on its in vivo CAR‑T platform. The company will make $785 million in initial payments, including a $465 million equity investment by Johnson & Johnson Innovation – JJDC Inc., and up to $140 million in contingent development milestone payments. Johnson & Johnson has an exclusive option to acquire Sail for $2.58 billion; payments will be allocated among Sail and its shareholders per the agreements.
Program scope and scientific approach
The collaboration will advance Sail’s lead immune‑mediated disease program and the broader in vivo CAR‑T platform. The platform is designed to reprogram a patient’s immune cells directly in the body with the stated goal of resetting the immune system to deliver durable, disease‑modifying control and potentially curative outcomes across immune‑mediated diseases and other targets over time.
Financial impact and conditions
Johnson & Johnson notes expected dilution to adjusted operational earnings per share and adjusted EPS of approximately $0.18 in 2026 and $1.28 in 2027 assuming exercise of the acquisition option. The transactions remain subject to applicable regulatory approvals and other closing conditions.
Source: J&J
